drugset
drugset / Trial / NCT00913133

Safety Study of Desirudin, an Anticoagulant for the Prophylaxis of Thrombosis

NCT00913133 ↗

Phase 4 Completed 516 enrolled Canyon Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The objective of this trial is to demonstrate the clinical utility of fixed-dose SC Desirudin for the prophylaxis of thrombosis as an alternative to heparin-based anticoagulation.

Timeline

Start
2010-03
Primary completion
2011-06
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Desirudin Protein / enzyme biologic 15 mg Subcutaneous

Indications

thrombotic disease